ClinicalTrials.gg
CompletedNCT05991323GLOBOSPINUpdated Oct 1, 2026

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

An observational study in Prurigo Nodularis, sponsored by Sanofi. Completed at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Sanofi · Observational

How we know · 3 judgments

Updated Oct 1, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.

Started
2023
with 2 others
Observational
2 of 23
1 open now
Registered
13th of 23
by date
Lead sponsor
2 of 23
Sanofi

Among the 23 studies in Prurigo with a site in United States, this one is one of 3 that started in 2023, is one of 2 observational ones, and was the 13th registered.

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Open to participants now

4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prurigo with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN).

The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN.

In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

Read the detailed description

The follow-up period will be 18 months or until death, loss to follow-up, or withdrawal, whichever comes first.

03

Conditions studied

  • Prurigo Nodularis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible participants who initiate dupilumab treatment for prurigo nodularis (according to the country-specific prescribing information)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older at the time of .
  • Physician decision to treat the patient with dupilumab for prurigo nodularis (according to the country-specific prescribing information) made prior to and independently of the patient's participation in the study.
  • Patients able to understand and complete study-related questionnaires.
  • Patients provide voluntary informed consent to participate in the study before inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who have a to dupilumab according to the country-specific prescribing information label.
  • Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short , substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of visits and assessments.
  • Patients currently participating in any interventional clinical trial.
  • Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
110 participants (actual)
Target follow-up
18 Months
Patient registry
Yes

Groups and cohorts

  • Patient with prurigo nodularis

    Participants aged 18 years or older who start receiving dupilumab for prurigo nodularis (according to the country-specific prescribing information) prior to and independently of their participation in the study

    Drug: Dupilumab

Interventions

  • Injection solution; subcutaneous

    Also known as: DUPIXENT, SAR231893

06

What researchers measure

Primary outcomes

  1. Frequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment

    Time frame: At baseline

  2. Frequency of reasons for dupilumab treatment modifications with the description of the modified treatment

    Time frame: From baseline up to month 18

  3. Proportion of patients who discontinued dupilumab

    Time frame: From baseline up to month 18

  4. Frequency of reasons for dupilumab treatment discontinuation

    Time frame: From baseline up to month 18

  5. Proportion of patients hospitalized due to PN

    Time frame: From baseline up to month 18

Secondary outcomes

  1. Baseline Characteristics: PN-related medical history

    (e.g., date of diagnosis, severity, comorbidities)

    Time frame: At baseline

  2. Baseline Characteristics: Socio-demographics of PN patients

    (e.g., month and year of birth (where allowed) or age, gender, race (if allowed), ethnicity (if allowed), Fitzpatrick skin type)

    Time frame: At baseline

  3. Baseline Characteristics: Type of PN therapies received prior to initiation of dupilumab treatment

    Time frame: At baseline

  4. Proportion of patients using concomitant medication

    Time frame: At baseline

  5. Proportion of patients with a ≥ four-point improvement (reduction) in Worst Itch Numeric Rating Scale (WI-NRS)

    The WI-NRS is a single-item Patient-Reported Outcomes (PRO). Patients will be asked to report the intensity of their worst pruritus (itch) using the 0 to 10 WI-NRS. Scores range from 0 to 10, with higher scores indicating greater itch intensity.

    Time frame: From baseline up to month 18

  6. Mean change in WI-NRS

    The WI-NRS is a single-item Patient-Reported Outcomes (PRO). Patients will be asked to report the intensity of their worst pruritus (itch) using the 0 to 10 WI-NRS. Scores range from 0 to 10, with higher scores indicating greater itch intensity.

    Time frame: From baseline up to month 18

  7. Proportion of patients with a ≥ four-point improvement (reduction) in Skin Pain Numeric Rating Scale (NRS)

    The Skin Pain NRS is a single-item Patient-Reported Outcomes (PRO). Patients indicate the intensity of their worst skin pain over the past 24 hours by selecting a number on the scale that ranges from 0 ("No pain") to 10 ("Worst pain imaginable"). Scores range from 0 to10, with higher scores indicating greater pain intensity.

    Time frame: From baseline up to month 18

  8. Mean change in Skin Pain NRS

    The Skin Pain NRS is a single-item Patient-Reported Outcomes (PRO). Patients indicate the intensity of their worst skin pain over the past 24 hours by selecting a number on the scale that ranges from 0 ("No pain") to 10 ("Worst pain imaginable"). Scores range from 0 to10, with higher scores indicating greater pain intensity.

    Time frame: From baseline up to month 18

  9. Proportion of patients with a ≥ two-point improvement (reduction) in Sleep Disturbance Numeric Rating Scale (NRS)

    The Sleep Disturbance NRS is a single-item Patient-Reported Outcomes (PRO). Patients will be asked to report the severity of their sleep disturbance using a 0 to 10 NRS. Scores range from 0 to10, with higher scores indicating worse sleep quality.

    Time frame: From baseline up to month 18

  10. Mean change in Sleep Disturbance NRS

    The Sleep Disturbance NRS is a single-item Patient-Reported Outcomes (PRO). Patients will be asked to report the severity of their sleep disturbance using a 0 to 10 NRS. Scores range from 0 to10, with higher scores indicating worse sleep quality.

    Time frame: From baseline up to month 18

  11. Proportion of patients with Patient Global Impression of Change of PN Disease (PGIC) score of "Very much better (improved)"

    The PGIC is a 7-point scale to assess patient health and determine if there has been an improvement or decline in clinical status. Scores range from 1 to 7, with higher score indicating worse health status.

    Time frame: From baseline up to month 18

  12. Proportion of patients with PGIC score of "Very much better (improved)" or "Moderately better (improved)"

    The PGIC is a 7-point scale to assess patient health and determine if there has been an improvement or decline in clinical status. Scores range from 1 to 7, with higher score indicating worse health status.

    Time frame: From baseline up to month 18

  13. Mean change in PGIC

    The PGIC is a 7-point scale to assess patient health and determine if there has been an improvement or decline in clinical status. Scores range from 1 to 7, with higher score indicating worse health status.

    Time frame: From baseline up to month 18

  14. Proportion of patients with Patient Global Impression of Severity of PN Disease (PGIS) score of "None"

    The PGIS is a one-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week. Scores range from 1 to 4, with higher score indicating worse symptom severity.

    Time frame: From baseline up to month 18

  15. Proportion of patients with PGIS score of "None" or "Mild"

    The PGIS is a one-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week. Scores range from 1 to 4, with higher score indicating worse symptom severity.

    Time frame: From baseline up to month 18

  16. Mean change in PGIS

    The PGIS is a one-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week. Scores range from 1 to 4, with higher score indicating worse symptom severity.

    Time frame: From baseline up to month 18

  17. Mean change in Dermatology Life Quality Index (DLQI)

    The DLQI is designed to measure the health-related quality of life of adults with a skin disease. The DLQI consists of 10 questions related to the effect of skin disease over the past week. Overall scoring ranges from 0 to 30, with a high score indicative of a poorer Health-Related Quality of Life (HRQoL)

    Time frame: From baseline up to month 18

  18. Mean change in Pruritus Activity Score (PAS)

    The modified PAS is a clinical-reported measure that evaluates the pruritic lesions. The modified questionnaire consists of five items: the type (visible lesions: item 1a; predominant lesions: item1b), estimated number (item 2), distribution (item 3), the representative body area and exact number of lesions (item 4), and the activity in terms of percentage of pruriginous lesions with excoriations/crusts on top (reflecting active scratching; item 5a) and the percentage of healed pruriginous lesions (reflecting healing of chronic prurigo; item 5b). The modified PAS will be completed based on the standard of care clinical assessment.

    Time frame: From baseline up to month 18

  19. Proportion of patients with Investigator's Global Assessment-chronic prurigo Activity (IGA-CPG Activity) score of 0 or 1

    The IGA-CPG Activity is an instrument used to assess the overall activity of chronic prurigo lesions at a given time point, as determined by the Investigator. In this context, nodules, papules, plaques and other PN related lesions are defined as pruriginous lesions or chronic prurigo lesions. The instrument consists of a five-point scale ranging from 0 to 4. Higher scores indicate severe CPG.

    Time frame: From baseline up to month 18

  20. Mean change in IGA-CPG Activity

    The IGA-CPG Activity is an instrument used to assess the overall activity of chronic prurigo lesions at a given time point, as determined by the Investigator. In this context, nodules, papules, plaques and other PN related lesions are defined as pruriginous lesions or chronic prurigo lesions. The instrument consists of a five-point scale ranging from 0 to 4. Higher scores indicate severe CPG.

    Time frame: From baseline up to month 18

  21. Proportion of patients with Investigator's Global Assessment-chronic prurigo Stage (IGA-CPG Stage) score of 0 or 1

    The IGA-CPG Stage is an instrument used to assess the overall number and thickness of chronic prurigo lesions at a given time point, as determined by the Investigator. In this context, nodules, papules, plaques and other PN related lesions are defined as pruriginous lesions or chronic prurigo lesions. The instrument consists of a five-point scale ranging from 0 to 4. Higher scores indicate severe CPG.

    Time frame: From baseline up to month 18

  22. Mean change in IGA-CPG Stage

    The IGA-CPG Stage is an instrument used to assess the overall number and thickness of chronic prurigo lesions at a given time point, as determined by the Investigator. In this context, nodules, papules, plaques and other PN related lesions are defined as pruriginous lesions or chronic prurigo lesions. The instrument consists of a five-point scale ranging from 0 to 4. Higher scores indicate severe CPG.

    Time frame: From baseline up to month 18

  23. Mean change in EQ-5D-5L

    The EQ-5D-5L comprises of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: From baseline up to month 18

  24. Mean change in Hospital Anxiety and Depression Scale (HADS) total score

    The HADS is a Patient-Reported Outcomes (PRO) instrument for screening anxiety and depression in non-psychiatric populations. The HADS consists of 14 items, 7 each for anxiety and depression symptoms. Patients select a response from 0 to 3 for each item, based on how they have been feeling in the past week. Scores range from 0 to 21 for each subscale. HADS anxiety (HADS-A) and HADS depression (HADS-D) scores ≤ 7 indicate no clinically relevant symptoms (normal), 8 to 10 borderline abnormal (borderline case), and 11 to 21 abnormal (maximum 21) indicating more severe symptoms.

    Time frame: From baseline up to month 18

  25. Proportion of patients reported working, absenteeism score, presenteeism score, and overall impairment working score using the Work Productivity and Activity Impairment (WPAI) questionnaire

    The Work Productivity and Activity Impairment General Health (WPAI-GH) is a 6-item Patient-Reported Outcomes (PRO) instrument that measures the effect of a condition on productivity during work and regular activities in the seven days prior to completion. The instrument comprises 4 domains: absenteeism, presenteeism, overall work impairment, and activity impairment due to health. WPAI-GH outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.

    Time frame: From baseline up to month 18

  26. Percentage of patients experiencing AEs and SAEs

    Time frame: From baseline up to month 18

07

Study locations

49 sites
  • Medical Dermatology Specialists Site Number : 8400005
    Phoenix, Arizona 85006-2754, United States
  • Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024
    Phoenix, Arizona 85008-3884, United States
  • Center for Dermatology Clinical Research- Site Number : 8400002
    Fremont, California 94538, United States
  • Halcyon Dermatology- Site Number : 8400023
    Laguna Hills, California 92653, United States
  • Mission Dermatology - Rancho Santa Margarita- Site Number : 8400015
    Rancho Santa Margarita, California 92688-3623, United States
  • Golden State Dermatology- Site Number : 8400014
    Walnut Creek, California 94598-3335, United States
  • Total Vein And Skin, LLC- Site Number : 8400019
    Boynton Beach, Florida 33437-3782, United States
  • GSI Clinical Research- Site Number : 8400017
    Margate, Florida 33063-7011, United States
  • Allergy Center at Brookstone Research - Centricity Research - PPDS- Site Number : 8400025
    Columbus, Georgia 31904, United States
  • Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave- Site Number : 8400003
    Indianapolis, Indiana 46250-2041, United States
  • Oakland Hills Dermatology - 3400 Auburn Rd- Site Number : 8400007
    Auburn Hills, Michigan 48326-3396, United States
  • Derm Institute of Western Michigan- Site Number : 8400034
    Caledonia, Michigan 49316-7478, United States
  • Dermatology Associates Western Michigan- Site Number : 8400033
    Grand Rapids, Michigan 49546-6204, United States
  • U.S. Dermatology Partners Lee's Summit- Site Number : 8400016
    Lee's Summit, Missouri 64064, United States
  • University of Nebraska - Lauritzen Outpatient Center- Site Number : 8400029
    Omaha, Nebraska 68105-1026, United States
  • Vivida Dermatology - Flamingo- Site Number : 8400013
    Las Vegas, Nevada 89119, United States
  • Las Vegas Dermatology- Site Number : 8400027
    Las Vegas, Nevada 89144-0518, United States
  • Duke Dermatology Clinic- Site Number : 8400026
    Durham, North Carolina 27710-4000, United States
  • Medical University of South Carolina (MUSC) - PPDS- Site Number : 8400001
    Charleston, South Carolina 29425-8903, United States
  • North Texas Center for Clinical Research- Site Number : 8400012
    Frisco, Texas 75034, United States
  • U.S. Dermatology Partners Longview- Site Number : 8400032
    Longview, Texas 75601, United States
  • Texas Tech University Health Sciences Center-125 W Hague Rd- Site Number : 8400010
    Lubbock, Texas 79430-0002, United States
  • West Virginia Research Institute- Site Number : 8400030
    Morgantown, West Virginia 26505-1873, United States
  • Investigational Site Number : 1240009
    Calgary, Alberta T2J 7E1, Canada
  • Investigational Site Number : 1240007
    Edmonton, Alberta T5K 2V4, Canada
  • Investigational Site Number : 1240012
    Surrey, British Columbia V3R 6A7, Canada
  • Investigational Site Number : 1240006
    Fredericton, New Brunswick E3B 1G9, Canada
  • Investigational Site Number : 1240004
    Ajax, Ontario L1S 7K8, Canada
  • Investigational Site Number : 1240003
    Barrie, Ontario L4M 7G1, Canada
  • Investigational Site Number : 1240011
    London, Ontario N6H 5L5, Canada
  • Investigational Site Number : 1240002
    Newmarket, Ontario L3Y 5G8, Canada
  • Investigational Site Number : 1240005
    Toronto, Ontario M2M 4J5, Canada
  • Investigational Site Number : 1240010
    Waterloo, Ontario N2J 1C4, Canada
  • Investigational Site Number : 1560009
    Guangzhou, Guangdong 510630, China
  • Investigational Site Number : 1560004
    Xi'an, Shaanxi 710004, China
  • Investigational Site Number : 1560003
    Jinan, Shandong 250001, China
  • Investigational Site Number : 1560008
    Hangzhou, Zhejiang 311400, China
  • Investigational Site Number : 1560010
    Wenzhou, Zhejiang 325000, China
  • Investigational Site Number : 1560007
    Beijing, 100050, China
  • Investigational Site Number : 1560005
    Beijing, 100083, China
  • Investigational Site Number : 1560006
    Shanghai, 200020, China
  • Investigational Site Number : 1560002
    Shenzhen, 518000, China
  • Investigational Site Number : 2500005
    Brest, Finistère 29606, France
  • Investigational Site Number : 2500001
    Nantes, 44000, France
  • Investigational Site Number : 3920001
    Obihiro, Hokkaido 080-0013, Japan
  • Investigational Site Number : 3920003
    Kyoto, 606-8507, Japan
  • Investigational Site Number : 3920004
    Matsudo, 271-0092, Japan
  • Investigational Site Number : 5280001
    Bergen op Zoom, North Brabant 4624 VT, Netherlands
  • Investigational Site Number : 5280002
    Hoofddorp, North Holland 2134 TM, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Sep 2026, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2023
First posted
Aug 14, 2023
StartActual
Dec 12, 2023
Primary completionActual
Sep 8, 2026
CompletionActual
Sep 8, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 1, 2026
Primary completion
Sep 22, 2026→Sep 8, 2026 (actual)
Oct 1, 2026
Study completion
Sep 22, 2026→Sep 8, 2026 (actual)
Oct 1, 2026
Enrollment
100 (estimated)→110 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Active, not recruiting→Completed
    Primary completion Sep 22, 2026→Sep 8, 2026 (now actual)
    Study completion Sep 22, 2026→Sep 8, 2026 (now actual)
    Enrollment 100 (estimated)→110 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05991323
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Dec 12, 2023
Primary completion
Sep 8, 2026
Completion
Sep 8, 2026
Last update
Oct 1, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion